Information de reference pour ce titreAccession Number: | 00001716-201706000-00003.
|
Author: | Kim, J. J. 1,2; Kim, D. *,3,4; Yim, J. Y. 3; Kang, J. H. 5; Han, K. H. 1; Kim, S. M. 1; Hwang, K. R. 6; Ku, S. Y. 2,7; Suh, C. S. 2,7; Kim, S. H. 2,7; Choi, Y. M. 2,7
|
Institution: | (1)Department of Obstetrics and Gynecology Healthcare System Gangnam Center Seoul National University Hospital Seoul Korea (2)The Institute of Reproductive Medicine and Population Medical Research Center Seoul National University College of Medicine Seoul Korea (3)Department of Internal Medicine Healthcare System Gangnam Center Seoul National University Hospital Seoul Korea (4)Division of Gastroenterology and Hepatology Stanford University School of Medicine Stanford CA USA (5)Department of Radiology Healthcare System Gangnam Center Seoul National University Hospital Seoul Korea (6)Department of Obstetrics and Gynecology Seoul Municipal Boramae Hospital Seoul Korea (7)Department of Obstetrics and Gynecology Seoul National University College of Medicine Seoul Korea
|
Title: | |
Source: | Alimentary Pharmacology & Therapeutics. 45(11):1403-1412, June 2017.
|
References: | 1. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-85.
2. Ruhl CE, Everhart JE. Fatty liver indices in the multiethnic United States National Health and Nutrition Examination Survey. Aliment Pharmacol Ther 2015; 41: 65-76.
3. Chen SH, He F, Zhou HL, et al. Relationship between nonalcoholic fatty liver disease and metabolic syndrome. J Dig Dis 2011; 12: 125-30.
4. Kim D, Kim WR. Nonobese fatty liver disease. Clin Gastroenterol Hepatol 2016. http://doi:10.1016/j.cgh.2016.08...- ouverture dans une nouvelle fenêtre [Epub ahead of print].
5. Leung JC, Loong TC, Wei JL, et al. Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients. Hepatology 2017; 65: 54-64.
6. Wei JL, Leung JC, Loong TC, et al. Prevalence and severity of nonalcoholic fatty liver disease in non-obese patients: a population study using proton-magnetic resonance spectroscopy. Am J Gastroenterol 2015; 110: 1306-14.
7. Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004; 89: 2745-9.
8. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005; 352: 1223-36.
9. Kim JJ, Hwang KR, Choi YM, et al. Complete phenotype and metabolic profiles of a large consecutive cohort of untreated Korean women with polycystic ovary syndrome. Fertil Steril 2014; 101: 1424-30.
10. Cerda C, Perez-Ayuso RM, Riquelme A, et al. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. J Hepatol 2007; 47: 412-7.
11. Zheng RH, Ding CF. Prevalence of nonalcoholic fatty liver disease in patients with polycystic ovary syndrome: a case-control study. Zhonghua Fu Chan Ke Za Zhi 2008; 43: 98-101.
12. Vassilatou E, Lafoyianni S, Vryonidou A, et al. Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome. Hum Reprod 2010; 25: 212-20.
13. Zueff LF, Martins WP, Vieira CS, et al. Ultrasonographic and laboratory markers of metabolic and cardiovascular disease risk in obese women with polycystic ovary syndrome. Ultrasound Obstet Gynecol 2012; 39: 341-7.
14. Karoli R, Fatima J, Chandra A, et al. Prevalence of hepatic steatosis in women with polycystic ovary syndrome. J Hum Reprod Sci 2013; 6: 9-14.
15. Qu Z, Zhu Y, Jiang J, et al. The clinical characteristics and etiological study of nonalcoholic fatty liver disease in Chinese women with PCOS. Iran J Reprod Med 2013; 11: 725-32.
16. Ramezani-Binabaj M, Motalebi M, Karimi-Sari H, et al. Are women with polycystic ovarian syndrome at a high risk of non-alcoholic fatty liver disease; a meta-analysis. Hepat Mon 2014; 14: e23235.
17. Romanowski MD, Parolin MB, Freitas AC, et al. Prevalence of non-alcoholic fatty liver disease in women with polycystic ovary syndrome and its correlation with metabolic syndrome. Arq Gastroenterol 2015; 52: 117-23.
18. Markou A, Androulakis II, Mourmouris C, et al. Hepatic steatosis in young lean insulin resistant women with polycystic ovary syndrome. Fertil Steril 2010; 93: 1220-6.
19. Chen MJ, Chiu HM, Chen CL, et al. Hyperandrogenemia is independently associated with elevated alanine aminotransferase activity in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2010; 95: 3332-41.
20. Mojiminiyi OA, Safar FH, AlRumaih H, et al. Variations in alanine aminotransferase levels within the normal range predict metabolic and androgenic phenotypes in women of reproductive age. Scand J Clin Lab Invest 2010; 70: 554-60.
21. Targher G, Rossini M, Lonardo A. Evidence that non-alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance: a novel hepato-ovarian axis? Endocrine 2016; 51: 211-21.
22. Yildiz BO, Bozdag G, Yapici Z, et al. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod 2012; 27: 3067-73.
23. Kim JJ, Choi YM, Cho YM, et al. Prevalence of elevated glycated hemoglobin in women with polycystic ovary syndrome. Hum Reprod 2012; 27: 1439-44.
24. Kim JJ, Chae SJ, Choi YM, et al. Atherogenic changes in low-density lipoprotein particle profiles were not observed in non-obese women with polycystic ovary syndrome. Hum Reprod 2013; 28: 1354-60.
25. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142: 1592-609.
26. World Health Organization Western Pacific Region . International Association for the Study of Obesity Task Force: The Asia-Pacific Perspective: Redefining Obesity and its Treatment. Sydney, Australia: Health Communications Australia, 2000; 15-21.
27. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group . Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41-7.
28. Kim JJ, Chae SJ, Choi YM, et al. Assessment of hirsutism among Korean women: results of a randomly selected sample of women seeking pre-employment physical check-up. Hum Reprod 2011; 26: 214-20.
29. Chae SJ, Kim JJ, Choi YM, et al. Clinical and biochemical characteristics of polycystic ovary syndrome in Korean women. Hum Reprod 2008; 23: 1924-31.
30. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745-50.
31. Lee JH, Kim D, Kim HJ, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis 2010; 42: 503-8.
32. Eckel RH, Alberti KG, Grundy SM, et al. The metabolic syndrome. Lancet 2010; 375: 181-3.
33. Lee S, Choi S, Kim HJ, et al. Cutoff values of surrogate measures of insulin resistance for metabolic syndrome in Korean non-diabetic adults. J Korean Med Sci 2006; 21: 695-700.
34. Baranova A, Tran TP, Birerdinc A, et al. Systematic review:association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2011; 33: 801-14.
35. Jones H, Sprung VS, Pugh CJ, et al. Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance. J Clin Endocrinol Metab 2012; 97: 3709-16.
36. McInnes KJ, Corbould A, Simpson ER, et al. Regulation of adenosine 5', monophosphate-activated protein kinase and lipogenesis by androgens contributes to visceral obesity in an estrogen-deficient state. Endocrinology 2006; 147: 5907-13.
37. Kanaya N, Vonderfecht S, Chen S. Androgen (dihydrotestosterone)-mediated regulation of food intake and obesity in female mice. J Steroid Biochem Mol Biol 2013; 138: 100-6.
38. Shen M, Shi H. Sex hormones and their receptors regulate liver energy homeostasis. Int J Endocrinol 2015. http://doi:10.1155/2015/294278- ouverture dans une nouvelle fenêtre [Epub ahead of print].
39. Schwimmer JB, Khorram O, Chiu V, et al. Abnormal aminotransferase activity in women with polycystic ovary syndrome. Fertil Steril 2005; 83: 494-7.
40. Setji TL, Holland ND, Sanders LL, et al. Nonalcoholic steatohepatitis and nonalcoholic fatty liver disease in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91: 1741-7.
41. Cicero AF, D'Addato S, Reggi A, et al. Hepatic steatosis index and lipid accumulation product as middle-term predictors of incident metabolic syndrome in a large population sample: data from the Brisighella Heart Study. Intern Emerg Med 2013; 8: 265-7.
42. Cicero AF, D'Addato S, Reggi A, et al. Gender difference in hepatic steatosis index and lipid accumulation product ability to predict incident metabolic syndrome in the historical cohort of the Brisighella Heart Study. Metab Syndr Relat Disord 2013; 11: 412-6.
|
Language: | English.
|
Document Type: | POLYCYSTIC OVARY SYNDROME WITH NAFLD.
|
Journal Subset: | Clinical Medicine. Pharmacology.
|
ISSN: | 0269-2813
|
NLM Journal Code: | a5d, 8707234
|
DOI Number: | https://dx.doi.org/10.1111/apt.1...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|